Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation

Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):131-146. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0451

View: 1464 Download: 174

Review

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782

View: 1962 Download: 180

Letter to the Editor

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):962-964. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264

View: 1801 Download: 105 Web of Science: 2 Crossref: 4

Original Article

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function

Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique

Clin Mol Hepatol. 2017;23(4):316-322. Published online August 22, 2017

DOI: https://doi.org/10.3350/cmh.2016.0087

View: 8303 Download: 193 Web of Science: 12 Crossref: 16

Editorial

Use of sofosbuvir in chronic kidney disease: Is it necessary?

Tae Seop Lim, Sang Hoon Ahn

Clin Mol Hepatol. 2017;23(4):308-310. Published online September 26, 2017

DOI: https://doi.org/10.3350/cmh.2017.0109

View: 6553 Download: 119 Web of Science: 4 Crossref: 6

Original Article

Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal

Yun Jung Choi, Jeong Han Kim, Ja Kyung Koo, Cho I Lee, Ji Young Lee, Jae Hoon Yang, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee

Clin Mol Hepatol. 2014;20(2):185-191. Published online June 30, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.2.185

View: 10381 Download: 122 Web of Science: 37 Crossref: 29

Correspondence

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Received January 28, 2025 Accepted February 6, 2025

DOI: https://doi.org/10.3350/cmh.2025.0100 [Accepted]

View: 206 Download: 12

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Received February 3, 2025 Accepted February 12, 2025

DOI: https://doi.org/10.3350/cmh.2025.0121 [Accepted]

View: 203 Download: 16

Review

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury – chronic kidney disease spectrum

Vishnu Girish, Rakhi Maiwall

Received November 24, 2024 Accepted March 24, 2025

DOI: https://doi.org/10.3350/cmh.2024.1060 [Accepted]

View: 35 Download: 4

1 |

Viewed By 7423	MAFLD: How is it different from NAFLD?
Viewed By 7038	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5613	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5364	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4792	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 270	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search